Newsroom Bayer

September
26,
2022
| 09:00 AM Europe/Amsterdam
Approval is based on the Phase III study FIREFLEYE and data from the follow-up study FIREFLEYE NEXT / Retinopathy of prematurity (ROP) can lead to severe visual impairment and blindness / With ROP, Eylea is now approved for six indications in
September
20,
2022
| 11:45 AM Europe/Amsterdam
New post-hoc analyses from the prespecified pooled analysis FIDELITY will provide insights into the effects of finerenone on kidney and cardiovascular outcomes by use of glucagon-like peptide-1 receptor agonists (GLP-1RA) at baseline, as well as by
September
11,
2022
| 10:15 AM Europe/Amsterdam
Consistent benefits were also seen in other patient-relevant endpoints, including all-cause and prostate cancer-related death and cumulative incidence of adverse events (AEs) of special interest
September
08,
2022
| 14:59 PM Europe/Amsterdam
Aflibercept 8 mg meets primary endpoints in two global pivotal studies in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) achieving non-inferior improvements in best corrected visual acuity to Eylea
September
02,
2022
| 10:15 AM Europe/Amsterdam
U.S. Food and Drug Administration (FDA) granted label update for Kerendia™ (finerenone) to include findings from the Phase III FIGARO-DKD cardiovascular (CV) outcomes study in patients with chronic kidney disease (CKD) associated with type 2
September
01,
2022
| 16:00 PM Europe/Amsterdam
Succeeds Fei-Fei Li, who stepped down at the end of August
August
30,
2022
| 14:00 PM Europe/Amsterdam
In prostate cancer, a key therapeutic area for Bayer, new patient-relevant data from the ARASENS Phase III study in metastatic hormone-sensitive prostate cancer (mHSPC) will be showcased, as well as data from the RALU study comprising real-world
August
29,
2022
| 09:24 AM Europe/Amsterdam

New data indicate positive effects of Kerendia™ (finerenone) on mortality in patients with chronic kidney disease and type 2 diabetes

Not intended for U.S. and UK Media - Late-breaking data from the prespecified pooled analysis FIDELITY presented at the European Society of Cardiology (ESC) Congress 2022

Data from FIDELITY, a prespecified pooled analysis of the Phase III FIDELIO-DKD and FIGARO-DKD studies, highlight the potential of Kerendia™ (finerenone) to reduce the incidence of sudden cardiac death / While in the overall FIDELITY population, the
August
28,
2022
| 09:14 AM Europe/Amsterdam
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or
August
23,
2022
| 08:05 AM Europe/Amsterdam
National Agency for Safety of Medicines and Health Products (ANSM) and French Ethics Committee approve protocol for trial expected to begin in Q4 2022 
August
22,
2022
| 09:00 AM Europe/Amsterdam
Late-breaking data from a new exploratory analysis of FIDELITY investigating causes of mortality in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) treated with Kerendia™ (finerenone) or placebo / New Phase IIb data from PACIFIC

Sign up for our Newsletter

We will keep you informed about the latest news.